John Parkinson

The study will examine the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis D virus RNA despite bulevirtide treatment.

Heather Clauss, MD, explains why Temple hires many of its fellows into full-time positions, why it is important for young providers to seek out mentors, and some strategies in learning how to navigate careers early-on.

Study investigators found a therapy designed to treat Celiac disease supported a more rapid return to normal activities for patients with multisystem inflammatory syndrome in children (MIS-C).

Aaron Mishkin, MD, discusses the prolific transplantation department at Temple University and how the infectious disease team, including the fellows, supports these lifesaving procedures.

Raven Boone, DO, discusses her experience in the Temple University fellowship program and what she is exposed to in terms of cases and learning opportunities.

In the second part of her interview, Temple’s Stephanie Spivack, MD, talks about how she works with different specialties at the hospital to help this marginalized population receive the care they need.

In the second part of an interview with Andrea Prinzi, PhD, MPH, SM(ASCP), she talks about how the March of Dimes played such a significant role against the disease, how the polio oral vaccine is a singular lesson that can be applied to medical science as a whole, and the understanding of the need to adapt to changing circumstances.

Andrea Prinzi, PhD, MPH, SM(ASCP), provides insights on how polio cases rose despite sanitation and hygiene improving as well as Jonas Salk’s and Albert Sabin's approaches to their vaccines' development.

Stephanie Spivack, MD, talks about the diverse educational experiences afforded to fellows during their time at Temple University as well as the devoted clinical care that serves the local community.

César de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.

This comes after the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) made the recommendation to remove the vaccine preservative.

In the largest world study, there was a 98% reduction in hospitalizations of babies who received the RSV vaccine compared with those who did not receive the RSV vaccine.

In the second installment of our Media Day interview, Temple University Hospital’s Rafik Samuel, MD, talks about what he has experienced as a clinician seeing patients with HIV before there were treatments available as well as his approach with fellows in teaching them about this disease.

Rafik Samuel, MD, chief of the Section of Infectious Disease at Temple University Hospital and professor of medicine at Lewis Katz School of Medicine at Temple University, talks about its history and the uniqueness of its fellowship program.

First author Jacek Skarbinski, MD, offers insights on new data published last week showing how this population can benefit from continued vaccination.

Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.

Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.

Cases and deaths in the state are down from the 2 previous years. Here are some clinical considerations, treatment options, and prevention strategies in relation to these infections.

In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.

A large study looked at booster uptake and effectiveness among US adults who received chemotherapy or immunotherapy.

Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.

The company said it expects to have its updated mRNA-1273 (Spikevax) vaccine available for these eligible populations in the US for the next respiratory virus season.

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Sara Embry discusses her experience with the infection while pregnant and as a mother to young children as well as finding the Peggy Lillis Foundation to help her cope with the infection and subsequently work as a peer support volunteer for the organization.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuing education opportunity.

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

The philanthropic organization plans to provide the gift over the next 5 years, and is in contrast with what is happening with US vaccine funding to the organization as well as the country's changing immunization policies.

Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.